KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity.

Sarbani G Laskar, Devendra Chaukar, Mandar Deshpande, Abhishek Chatterjee, Shwetabh Sinha, Santam Chakraborty, Jai P Agarwal, Tejpal Gupta, Ashwini Budrukkar, Vedang Murthy, Prathamesh Pai, Pankaj Chaturvedi, Gouri Pantvaidya, Anuja Deshmukh, Deepa Nair, Sudhir Nair, Kumar Prabhash, Monali Swain, Anuj Kumar, Vanita Noronha, Vijay Patil, Amit Joshi, Anil DCruz

Eur J Cancer 181 179-187

PMID36669426
PMCID-
DOI10.1016/j.ejca.2022.12.016
发表日期2023-01-20
入排依据:The trial is a Phase III randomized study with time-to-event endpoints (DFS, OS) in oncology. However, the abstract does not specify the chemotherapy agent used in the concurrent chemoradiation arm, and the intervention is primarily described as radiation therapy intensification. Without explicit evidence of a specific drug intervention, the 'drug_intervention' criterion is not met.
摘要

摘要

BACKGROUND: Limited data exists regarding the impact of intensification of adjuvant therapy in resected Oral Cavity Squamous Cell Carcinomas (OCSCC) with adverse prognostic features on histopathology. PATIENTS AND METHODS: This was a three-arm phase III, randomised trial including patients with resected advanced OCSCC. Randomisation was done in a 1:1:1 ratio: Arm-A- standard adjuvant radiation therapy (RT) 60Gy/30 fractions over 6 weeks versus Arm-B-concurrent chemoradiation versus Arm-C-accelerated radiation therapy (6 d a week). The trial was powered to detect an absolute difference of 10% in 5-year Locoregional Control (LRC). RESULTS: The trial was conducted between June 2005 and March 2013. Majority of the patients were males, had T3-T4 disease, had N2-N3 nodal status and had Extra-Capsular Extension (ECE) in nodes. The median follow-up was 95.9 months. There was no difference between the three arms (A versus B versus C) for 10-year locoregional control (LRC): 60.2% versus 61.4% versus 65.7%, p = 0.57; disease free survival (DFS): 37.4% versus 43.9% versus 39.6%, p = 0.40; or Overall Survival (OS): 39.7% versus 46.6% versus 40.4%, p = 0.40. There was no benefit of intensification with either modality in patients with any single adverse pathological factor. A benefit of intensification could be seen in patients with a combination of high-risk features: T3-T4 primary tumours with N2-N3 nodes along with ECE for DFS (Arm B versus Arm A HR) = 0.53, Arm C versus Arm A HR = 0.63) and OS (Arm B versus Arm A HR = 0.58, Arm C versus Arm A HR = 0.60). CONCLUSIONS: All optimally resected OCSCC with adverse features did not benefit from intensification of adjuvant therapy. Only a cohort of patients with a combination of high-risk features are likely candidates for intensification. CLINICAL TRIAL REGISTRATION: NCT00193843.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。